Department of Ophthalmology and Visual Sciences, Carver College of Medicine, University of Iowa, Iowa City.
Institute for Vision Research, University of Iowa, Iowa City.
JAMA Ophthalmol. 2019 May 1;137(5):559-563. doi: 10.1001/jamaophthalmol.2019.0005.
Mutations in the myocilin (MYOC) gene are the most common molecularly defined cause of primary open-angle glaucoma that typically occurs in patients with high intraocular pressures (IOP). One MYOC mutation, p.Gln368Ter, has been associated with as many as 1.6% of primary open-angle glaucoma cases that had a mean maximum recorded IOP of 30 mm Hg. However, to our knowledge, the role of the p.Gln368Ter mutation in patients with normal-tension glaucoma (NTG) with an IOP of 21 mm Hg or lower has not been investigated.
To evaluate the role of the p.Gln368Ter MYOC mutation in patients with NTG.
DESIGN, SETTING, AND PARTICIPANTS: In this case-control study of the prevalence of the p.Gln368Ter mutation in patients with NTG, cohort 1 was composed of 772 patients with NTG and 2152 controls from the United States (Iowa, Minnesota, and New York) and England and cohort 2 was composed of 561 patients with NTG and 2606 controls from the Massachusetts Eye and Ear Infirmary and the NEIGHBORHOOD consortium. Genotyping was conducted using real-time polymerase chain reaction that was confirmed with Sanger sequencing, the imputation of genome-wide association study data, or an analysis of whole-exome sequence data. Data analysis occurred between April 2007 and April 2018.
Comparison of the frequency of the p.Gln368Ter MYOC mutation between NTG cases and controls with the Fisher exact test.
Of 6091 total participants, 3346 (54.9%) were women and 5799 (95.2%) were white. We detected the p.Gln368Ter mutation in 7 of 772 patients with NTG (0.91%) and 7 of 2152 controls (0.33%) in cohort 1 (P = .03). In cohort 2, we detected the p.Gln368Ter mutation in 4 of 561 patients with NTG (0.71%) and 10 of 2606 controls (0.38%; P = .15). When the cohorts were analyzed as a group, the p.Gln368Ter mutation was associated with NTG (odds ratio, 2.3; 95% CI, 0.98-5.3; P = .04).
In cohorts 1 and 2, the p.Gln368Ter mutation in MYOC was found in patients with IOPs that were 21 mm Hg or lower (NTG), although at a frequency that is lower than previously detected in patients with higher IOP. These data suggest that the p.Gln368Ter mutation may be associated with glaucoma in patients with normal IOPs as well as in patients with IOPs that are greater than 21 mm Hg.
MYOC 基因中的突变是原发性开角型青光眼最常见的分子定义原因,这种青光眼通常发生在眼内压(IOP)较高的患者中。MYOC 基因的一个突变,p.Gln368Ter,与高达 1.6%的原发性开角型青光眼病例有关,这些病例的平均最大记录 IOP 为 30mmHg。然而,据我们所知,p.Gln368Ter 突变在眼压为 21mmHg 或更低的正常眼压性青光眼(NTG)患者中的作用尚未得到研究。
评估 p.Gln368Ter MYOC 突变在 NTG 患者中的作用。
设计、地点和参与者:在这项关于 NTG 患者中 p.Gln368Ter 突变流行率的病例对照研究中,队列 1 由来自美国(爱荷华州、明尼苏达州和纽约州)和英国的 772 名 NTG 患者和 2152 名对照组成,队列 2 由来自马萨诸塞州眼耳医院和 NEIGHBORHOOD 联盟的 561 名 NTG 患者和 2606 名对照组成。使用实时聚合酶链反应进行基因分型,通过 Sanger 测序、全基因组关联研究数据的推断或全外显子组序列数据的分析进行确认。数据分析于 2007 年 4 月至 2018 年 4 月进行。
采用 Fisher 精确检验比较 NTG 病例与对照组中 p.Gln368Ter MYOC 突变的频率。
在 6091 名参与者中,3346 名(54.9%)为女性,5799 名(95.2%)为白人。我们在队列 1 中检测到 772 名 NTG 患者中有 7 名(0.91%)和 2152 名对照中有 7 名(0.33%)携带 p.Gln368Ter 突变(P=0.03)。在队列 2 中,我们在 561 名 NTG 患者中有 4 名(0.71%)和 2606 名对照中有 10 名(0.38%)携带 p.Gln368Ter 突变(P=0.15)。当将两个队列作为一个整体进行分析时,p.Gln368Ter 突变与 NTG 相关(优势比,2.3;95%置信区间,0.98-5.3;P=0.04)。
在队列 1 和 2 中,MYOC 中的 p.Gln368Ter 突变存在于 IOP 为 21mmHg 或更低的患者(NTG)中,尽管其频率低于先前在 IOP 较高的患者中检测到的频率。这些数据表明,p.Gln368Ter 突变可能与正常 IOP 患者以及 IOP 大于 21mmHg 的患者的青光眼有关。